TRIO041/REPLACE

Phase III, Multicenter, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of Regorafenib in Combination With Pembrolizumab Versus TACE for First-Line Treatment of Intermediate-Stage HCC With Beyond Up-to-7 Criteria

ClinicalTrials.Gov
View All Studies